SiRNF8 Delivered by DNA Framework Nucleic Acid Effectively Sensitizes Chemotherapy in Colon Cancer

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Inter J Can. 2021;149:778–789. doi:10.1002/ijc.33588
   Web of Science ®Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669–685. doi:10.1001/jama.2021.0106
   PubMed Web of Science ®Google Scholar
• Khan FAO, Albalawi R, Pottoo FH. Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment. Med Res Rev. 2022;42(1):227–258. doi:10.1002/med.21809
   PubMed Web of Science ®Google Scholar
• Li P, Zhang X, Wang H, et al. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol Cancer Ther. 2017;16:739–751. doi:10.1158/1535-7163.MCT-16-0591
   PubMed Web of Science ®Google Scholar
• Zhu C, Zhang L, Zhao S, Dai W, Xu Y. UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer. Cell Death Dis. 2021;12(6):519. doi:10.1038/s41419-021-03798-2
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree? Redox Biol. 2020;29:101394. doi:10.1016/j.redox.2019.101394
   PubMed Web of Science ®Google Scholar
• Renu K, V.g A, P.b TP, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy – an update. Eur J Pharmacol. 2018;818:241–253. doi:10.1016/j.ejphar.2017.10.043
   PubMed Web of Science ®Google Scholar
• Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708. doi:10.1016/j.biopha.2021.111708
   PubMed Web of Science ®Google Scholar
• Alibolandi M, Abnous K, Mohammadi M, et al. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation. J Control Release. 2017;264:228–236. doi:10.1016/j.jconrel.2017.08.030
   PubMed Web of Science ®Google Scholar
• Russell LM, Hultz M, Searson PC. Leakage kinetics of the liposomal chemotherapeutic agent Doxil: the role of dissolution, protonation, and passive transport, and implications for mechanism of action. J Control Release. 2018;269:171–176. doi:10.1016/j.jconrel.2017.11.007
   PubMed Web of Science ®Google Scholar
• Hosseini NF, Amini R, Ramezani M, et al. AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer. Biomed Pharmacother. 2022;155:113690. doi:10.1016/j.biopha.2022.113690
   PubMed Web of Science ®Google Scholar
• Christidi E, Brunham LA-O. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12(4):339. doi:10.1038/s41419-021-03614-x
   PubMed Web of Science ®Google Scholar
• Wu L, Wang L, Du Y, Zhang Y, Ren J. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity. Trends Pharmacol Sci. 2023;44:34–49. doi:10.1016/j.tips.2022.10.003
   PubMed Web of Science ®Google Scholar
• Guo Z, Tian Y, Guo Y, et al. RAD6B plays a critical role in neuronal DNA damage response to resist neurodegeneration. Front Cell Neurosci. 2019;13:392. doi:10.3389/fncel.2019.00392
   PubMed Web of Science ®Google Scholar
• Guo Y, Song Y, Guo Z, et al. Function of RAD6B and RNF8 in spermatogenesis. Cell Cycle. 2018;17:162–173. doi:10.1080/15384101.2017.1361066
   PubMed Web of Science ®Google Scholar
• Zhou T, Yi F, Wang Z, et al. The Functions of DNA Damage Factor RNF8 in the pathogenesis and progression of cancer. Int J Bio Sci. 2019;15(5):909. doi:10.7150/ijbs.31972
   Google Scholar
• Ouyang S, Song Y, Tian Y, et al. RNF8 deficiency results in neurodegeneration in mice. Neurobiol Aging. 2015;36:2850–2860. doi:10.1016/j.neurobiolaging.2015.07.010
   PubMed Web of Science ®Google Scholar
• Tracz MA-O, Bialek WA-O. Beyond K48 and K63: non-canonical protein ubiquitination. Cell Mol Biol Lett. 2021;26(1):1. doi:10.1186/s11658-020-00245-6
   PubMed Web of Science ®Google Scholar
• Martínez-Férriz A, Ferrando A, Fathinajafabadi A, Farràs R. Ubiquitin-mediated mechanisms of translational control. Semin Cell Dev Biol. 2022;132:146–154. doi:10.1016/j.semcdb.2021.12.009
   PubMed Web of Science ®Google Scholar
• Kolla S, Ye M, Mark KG, Rapé M. Assembly and function of branched ubiquitin chains. Trends Biochem Sci. 2022;2022:1.
   Google Scholar
• Cao L, Liu X, Zheng B, Xing CA-OX, Liu JA-O. Role of K63-linked ubiquitination in cancer. Cell Death Discovery. 2022;8(1):410. doi:10.1038/s41420-022-01204-0
   PubMed Web of Science ®Google Scholar
• Li L, Halaby M-J, Hakem A, et al. Rnf8 deficiency impairs class switch recombination, spermatogenesis, and genomic integrity and predisposes for cancer. J Exp Med. 2010;207(5):983–997. doi:10.1084/jem.20092437
   PubMed Web of Science ®Google Scholar
• Ren L, Zhou T, Wang Y, et al. RNF8 induces β-catenin-mediated c-Myc expression and promotes colon cancer proliferation. Int J Bio Sci. 2020;16(12):2051. doi:10.7150/ijbs.44119
   Google Scholar
• Kuang J, Min L, Liu C, Chen S, Zhu L. RNF8 promotes epithelial-mesenchymal transition in lung cancer cells via stabilization of slug. Mol Cancer Res. 2020;1211:2019.
   Google Scholar
• Kuang J, Li L, Guo L, et al. RNF8 promotes epithelial-mesenchymal transition of breast cancer cells. J Exp Clin Cancer Res. 2016;35(1):1–4. doi:10.1186/s13046-016-0363-6
   PubMedGoogle Scholar
• Zhou T, Wang S, Song X, et al. RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression. Cell Death Dis. 2022;13(4):352. doi:10.1038/s41419-022-04787-9
   PubMed Web of Science ®Google Scholar
• Xu Y, Hu Y, Xu T, et al. RNF8-mediated regulation of Akt promotes lung cancer cell survival and resistance to DNA damage. Cell Rep. 2021;37:109854. doi:10.1016/j.celrep.2021.109854
   PubMed Web of Science ®Google Scholar
• Lee HJ, Li C-F, Ruan D, et al. The DNA damage transducer RNF8 facilitates cancer chemoresistance and progression through twist activation. Molecular Cell. 2016;63(6):1021–1033. doi:10.1016/j.molcel.2016.08.009
   PubMed Web of Science ®Google Scholar
• Gogoi P, Kaur G, Singh NK. Nanotechnology for colorectal cancer detection and treatment. World J Gastroenterol. 2022;28(46):6497. doi:10.3748/wjg.v28.i46.6497
   PubMed Web of Science ®Google Scholar
• Kasi PB, Mallela VR, Ambrozkiewicz F, et al. Theranostics nanomedicine applications for colorectal cancer and metastasis: recent advances. Int J Mol Sci. 2023;24(9):7922. doi:10.3390/ijms24097922
   PubMed Web of Science ®Google Scholar
• Haggag Y, Elshikh M, El-Tanani M, et al. Nanoencapsulation of sophorolipids in PEGylated poly(lactide-co-glycolide) as a novel approach to target colon carcinoma in the murine model. Drug Delivery Transl Res. 2020;10:1353–1366. doi:10.1007/s13346-020-00750-3
   PubMed Web of Science ®Google Scholar
• Ibrahim B, Mady OY, Tambuwala MM, Haggag YA. pH-sensitive nanoparticles containing 5-fluorouracil and leucovorin as an improved anti-cancer option for colon cancer. Nanomedicine. 2022;17:367–381. doi:10.2217/nnm-2021-0423
   PubMed Web of Science ®Google Scholar
• Pavitra E, Dariya B, Srivani G, et al. Engineered nanoparticles for imaging and drug delivery in colorectal cancer. Semi Cancer Biol. 2021;69:293–306. doi:10.1016/j.semcancer.2019.06.017
   PubMed Web of Science ®Google Scholar
• Younis NK, Roumieh R, Bassil EP, et al. Nanoparticles: attractive tools to treat colorectal cancer. Semi Cancer Biol. 2022;86:1–13. doi:10.1016/j.semcancer.2022.08.006
   PubMed Web of Science ®Google Scholar
• Naeimi R, Najafi R, Molaei P, Amini R, Pecic S. Nanoparticles: the future of effective diagnosis and treatment of colorectal cancer? Eur J Pharmacol. 2022;936:175350. doi:10.1016/j.ejphar.2022.175350
   PubMed Web of Science ®Google Scholar
• Rothemund PW. Folding DNA to create nanoscale shapes and patterns. Nature. 2006;440(7082):297–302. doi:10.1038/nature04586
   PubMed Web of Science ®Google Scholar
• Udomprasert A, Kangsamaksin TA-O. DNA origami applications in cancer therapy. Cancer Sci. 2017;108(8):1535–1543. doi:10.1111/cas.13290
   PubMed Web of Science ®Google Scholar
• Hong F, Zhang F, Liu Y, Yan HA-O. DNA origami: scaffolds for creating higher order structures. Chem. Rev. 2017;117(20):12584–12640. doi:10.1021/acs.chemrev.6b00825
   PubMed Web of Science ®Google Scholar
• Zeng Y, Nixon RL, Liu W, Wang R. The applications of functionalized DNA nanostructures in bioimaging and cancer therapy. Biomaterials. 2021;268:120560. doi:10.1016/j.biomaterials.2020.120560
   PubMed Web of Science ®Google Scholar
• Ji JA-O, Karna DA-O, Mao HA-O. DNA origami nano-mechanics. Chem Soc Rev. 2021;50(21):11966–11978. doi:10.1039/D1CS00250C
   PubMed Web of Science ®Google Scholar
• Jiang Q, Liu S, Liu J, Wang ZG, Ding BA-O. Rationally designed DNA-origami nanomaterials for drug delivery in vivo. Adv Mater. 2019;31(45):1804785. doi:10.1002/adma.201804785
   Web of Science ®Google Scholar
• Wiraja C, Zhu Y, Lio DCS, et al. Framework nucleic acids as programmable carrier for transdermal drug delivery. Nat Commun. 2019;10(1):1147. doi:10.1038/s41467-019-09029-9
   PubMedGoogle Scholar
• Ouyang X, Wu Y, Guo L, et al. Self-assembly induced enhanced electrochemiluminescence of copper nanoclusters using DNA nanoribbon templates. Angew Chem Int. 2023;62(21):e202300893. doi:10.1002/anie.202300893
   PubMed Web of Science ®Google Scholar
• Ouyang XA-O, Wang S-Y, Liu T, et al. Functional modulation of cytochrome C upon specific binding to DNA nanoribbons. Chem. Commun. 2019;55(93):14074–14077. doi:10.1039/C9CC05427H
   PubMed Web of Science ®Google Scholar
• Linko V, Ora A, Kostiainen MA. DNA nanostructures as smart drug-delivery vehicles and molecular devices. Trends Biotechnol. 2015;33:586–594. doi:10.1016/j.tibtech.2015.08.001
   PubMed Web of Science ®Google Scholar
• Jorge AF, Aviñó A, Pais AA, Eritja R, Fàbrega C. Fàbrega C DNA-based nanoscaffolds as vehicles for 5-fluoro-2’-deoxyuridine oligomers in colorectal cancer therapy. Nanoscale. 2018;10(15):7238–7249. doi:10.1039/C7NR08442K
   PubMed Web of Science ®Google Scholar
• Wang Z, Song L, Liu Q, et al. A tubular DNA Nanodevice as a siRNA/chemo-drug co-delivery vehicle for combined cancer therapy. Angew Chem. 2021;133(5):2626–2630. doi:10.1002/ange.202009842
   Google Scholar
• Xu T, Yu S, Sun Y, et al. DNA origami frameworks enabled self-protective siRNA delivery for dual enhancement of chemo-photothermal combination therapy. Small. 2021;17(46):2101780. doi:10.1002/smll.202101780
   Web of Science ®Google Scholar
• Pan QA-O, Nie C, Hu Y, et al. Aptamer-functionalized DNA origami for targeted codelivery of antisense oligonucleotides and doxorubicin to enhance therapy in drug-resistant cancer cells. ACS Appl Mater Interfaces. 2019;12(1):400–409. doi:10.1021/acsami.9b20707
   PubMed Web of Science ®Google Scholar
• Liu J, Song L, Liu S, et al. A Tailored DNA nanoplatform for synergistic RNAi-/chemotherapy of multidrug-resistant tumors. Angew Chem Int. 2018;57:15486–15490. doi:10.1002/anie.201809452
   PubMed Web of Science ®Google Scholar
• Xiao D, Li Y, Tian T, et al. Tetrahedral framework nucleic acids loaded with aptamer AS1411 for siRNA delivery and gene silencing in malignant melanoma. ACS Appl Mater Interfaces. 2021;13:6109–6118. doi:10.1021/acsami.0c23005
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Karthikeyan SK, Korla PK, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27. doi:10.1016/j.neo.2022.01.001
   PubMed Web of Science ®Google Scholar
• Ghosh S, Singh R, Vanwinkle ZM, et al. Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis. Theranostics. 2022;12(12):5574. doi:10.7150/thno.70754
   PubMed Web of Science ®Google Scholar
• Wang H, Yang W, Qin Q, et al. E3 ubiquitin ligase MAGI3 degrades c-Myc and acts as a predictor for chemotherapy response in colorectal cancer. Mol Cancer. 2022;21(1):1–9. doi:10.1186/s12943-022-01622-9
   PubMed Web of Science ®Google Scholar
• Zeng Y, Liu J, Yang S, et al. Time-lapse live cell imaging to monitor doxorubicin release from DNA origami nanostructures. J Mat Chem B. 2018;6(11):1605–1612. doi:10.1039/C7TB03223D
   PubMed Web of Science ®Google Scholar
• Li M, Yang G, Zheng Y, et al. NIR/pH-triggered aptamer-functionalized DNA origami nanovehicle for imaging-guided chemo-phototherapy. J Nanobiotechnol. 2023;21(1):186. doi:10.1186/s12951-023-01953-9
   PubMed Web of Science ®Google Scholar
• Zhang H, Wei X, Liu L, Zhang Q, Jiang W. The role of positively charged sites in the interaction between model cell membranes and γ-Fe(2)O(3) NPs. Sci Total Environ. 2019;673:414–423. doi:10.1016/j.scitotenv.2019.04.074
   PubMed Web of Science ®Google Scholar
• Xie S, Sun W, Fu T, et al. Aptamer-based targeted delivery of functional nucleic acids. J Am Chem Soc. 2023;145:7677–7691. doi:10.1021/jacs.3c00841
   PubMed Web of Science ®Google Scholar
• Fao S, Zeeshan M, Laraib U, et al. DNA based and stimuli-responsive smart nanocarrier for diagnosis and treatment of cancer: applications and challenges. Cancers. 2021;13(14):3396. doi:10.3390/cancers13143396.
   PubMed Web of Science ®Google Scholar
• Huen MS, Grant R, Manke I, et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell. 2007;131(5):901–914. doi:10.1016/j.cell.2007.09.041
   PubMed Web of Science ®Google Scholar
• Deshar R, Yoo W, Cho EB, Kim S, Yoon JB. RNF8 mediates NONO degradation following UV-induced DNA damage to properly terminate ATR-CHK1 checkpoint signaling. Nucleic Acids Res. 2019;47(2):762–778. doi:10.1093/nar/gky1166
   PubMed Web of Science ®Google Scholar
• Sun J, Zhu Z, Li W, et al. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res. 2020;39(1):1–8. doi:10.1186/s13046-020-01734-4
   PubMed Web of Science ®Google Scholar
• Geißler DA-O, Wegmann M, Jochum T, et al. An automatable platform for genotoxicity testing of nanomaterials based on the fluorometric γ-H2AX assay reveals no genotoxicity of properly surface-shielded cadmium-based quantum dots. Nanoscale. 2019;11(28):13458–13468. doi:10.1039/C9NR01021A
   PubMed Web of Science ®Google Scholar
• Zhang B, Li F, Shen L, et al. A cathodic photoelectrochemical immunoassay with dual signal amplification for the ultrasensitive detection of DNA damage biomarkers. Biosens Bioelectron. 2023;224:115052. doi:10.1016/j.bios.2022.115052
   PubMed Web of Science ®Google Scholar
• Li F, Liu B, Zhou X, Xu Q. Silencing of E3 ubiquitin ligase RNF8 enhances ionizing radiation sensitivity of medulloblastoma cells by promoting the deubiquitination of PCNA. Oncology Res. 2018;26(9):1365. doi:10.3727/096504018X15154085345907
   PubMed Web of Science ®Google Scholar
• Deng S, Yan T, Jendrny C, et al. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014;14:1. doi:10.1186/1471-2407-14-842
   PubMed Web of Science ®Google Scholar
• Marin JA-O, Monte MJ, Macias RI, et al. Expression of chemoresistance-associated ABC proteins in hepatobiliary, pancreatic and gastrointestinal cancers. Cancers. 2022;14(14):3524.
   PubMed Web of Science ®Google Scholar
• Low FG, Shabir KAO, Brown JE, Rao. B, Rothnie AJ. Roles of ABCC1 and ABCC4 in proliferation and migration of breast cancer cell lines. Int J Mol Sci. 2020;21(20):7664. doi:10.3390/ijms21207664
   PubMed Web of Science ®Google Scholar
• Ramos A, Sadeghi S, Tabatabaeian HAO. Battling chemoresistance in cancer: root causes and strategies to uproot them. Int J Mol Sci. 2021;22(17):9451. doi:10.3390/ijms22179451
   PubMed Web of Science ®Google Scholar
• Gao Q, Li -X-X, Xu Y-M, et al. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. Cancer Lett. 2020;476:67–74. doi:10.1016/j.canlet.2020.02.007
   PubMed Web of Science ®Google Scholar